By in

Share Placing completed to Miton Asset Management

Press Release                                                                                                      Thursday 28th June 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Share Placing completed to Miton Asset Management

Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, announces that the share Placing of 12,500,000 new Ordinary Shares at a subscription price of 4 pence per share announced on Wednesday 27 June, raising £500,000 before expenses, has been successfully completed with LF Miton UK Smaller Companies Fund.

Following admission of the Placing shares, the Company’s enlarged issued share capital will comprise 436,900,000 Ordinary Shares.

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private. Sativa Investments’ first two deals include Canadian-based, tri-listed, emerging global pharmaceutical company,Veritas Pharma Inc., and Toronto-based Pharma-Tech company that owns the patent-pending proprietary QuickStrip™ technology, Rapid Dose Therapeutics Inc.

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.

For more information on Sativa Investments, please visit: https://sativainvestments.com/

By in

Orderly Market Agreement - Director’s Dealing

                                                                                                                                                                                     25 June 2018

Sativa Investments PLC

 (“Sativa” or the “Company”)

Orderly Market Agreement – Director’s Dealing

Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, announces that today, 25 June 2018, Mark Blower, an executive director of the Company, sold 1,000,000 ordinary shares of £0.0025 at a price of £0.04 per share and Noel Lyons, a non-executive Director of the Company, sold 500,000 ordinary shares of £0.0025 each in the Company at a price of £0.0425, pursuant to an orderly market agreement to satisfy market demand.

As announced on 29 March 2018, the Directors agreed to make available their allocated options for sale through Peterhouse should there be sufficient demand in the market following Admission. Mark Blower has today exercised 1,000,000 Options at a price of 0.5p per share and Noel Lyons has exercised 500,000 Options at a price of 0.5p per share.

No fees of any nature are payable to Peterhouse in respect of the orderly market arrangements.

Following the exercise of 1,500,000 Options in total, referred to above, the Company has 424,400,000 Ordinary Shares in issue. The total number of Ordinary Shares with voting rights is now 424,400,000 Ordinary Shares.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information please contact:

 

Geremy Thomas
Founder & CEO
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller
Peterhouse Capital Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /
Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/

By in

Sativa Foundation to fund academic research in to medicinal cannabis

Press Release                                                                                                       Monday 25th June 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Sativa Foundation to fund academic research in to medicinal cannabis

Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, has formed the Sativa Foundation (“The Foundation”) to fund academic research into medicinal cannabis and its benefits to the pharmaceutical and healthcare sectors. The Foundation will award grants to research projects approved by the Foundation’s Advisory Board, which includes Pharmacologist Sir Alasdair Breckenridge, physician and barrister Dr Peter Feldshreiber, physician Dr Stuart Ungar, and founder and Chief Executive Officer of Sativa Investments, Geremy Thomas. Three research grants are already being considered.  

Sativa Investments will have a fiduciary interest in any grant, as each will be conditional on Sativa Research and Development Ltd, a wholly owned subsidiary of Sativa Investments PLC, being entitled to the entire IP and licensing rights to any discovery or other agreed terms. Commercialisation agreements will be agreed between the parties, and Home Office growing licenses will be sought to supply materials to the researchers.

Geremy Thomas said: “Medicinal cannabis in the UK is becoming a major pharmaceutical and healthcare solution to treat patients’ symptoms without the side effects from opioids. Medicinal cannabis needs to be far more thoroughly researched in the UK and Sativa is delighted to be helping to fund it.

“The Board looks forward to help lead medicinal cannabis research in the UK, so its use can be implemented in the best way possible for better patient outcome.”

The Directors of the Company accept responsibility for the contents of this announcement.

– Ends  –

 

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/

By in

Sativa agrees purchase of 100% of CBD product provider George Botanicals

Press Release                                                                                                              Friday 22 June 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Sativa agrees purchase of 100% of CBD product provider George Botanicals 

Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, has agreed to purchase, for £415,000, 100 per cent of George Botanicals Ltd, a UK-based manufacturer, wholesaler and distributor of wellness CBD products, following the Memorandum of Understanding announced by Sativa on Tuesday 17 April, 2018. The Company will pay £215,000 in cash and £200,000 in shares in Sativa at £0.04 per share.

The vendor is Carbon Managers Limited (“Carbon Managers”), of which Sativa’s Chief Executive Officer, Geremy Thomas, is the 100 per cent shareholder. Geremy Thomas and George Thomas are significant shareholders in Sativa and both are also Directors of Carbon Managers. Pursuant to the NEX Exchange Growth Market Rules for Issuers, the transaction would therefore constitute a related party transaction. Geremy Thomas is not involved in any of Sativa’s decision-making process in relation to this purchase.   

Mark Blower, Executive Director of Sativa Investments, said: “There are 365,000 confirmed users of CBD oil in the UK today and the market over the next two years will be worth £100 million, according to the Cannabis Trades Association. George Botanicals is well-placed to gain a significant market share.”

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

For further information please contact:

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.   

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/

By in

Sativa passes resolution at General Meeting to broaden investment policy

Press Release                                                                                                              Friday 22 June 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Sativa passes resolution at General Meeting to broaden investment policyto meet widening global demand for medicinal cannabis

Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, announces that all Resolutions were passed by the requisite majority at the Company’s General Meeting today, including Resolutions to broaden its investment strategy beyond Canada, the authority to allot shares, and the disapplication of pre-emption rights.

Since listing on the NEX Exchange Growth Market on Thursday 29th March 2018, Sativa has pursued numerous potential investments and has already announced that it has completed two investments, these being in Veritas Pharma Inc. and Rapid Dose Therapeutics Inc. on 21 May and 23 May respectively. This week, the Company appointed pharmacologist Sir Alasdair Breckenridge, to its already heavyweight Advisory Board, to assist Sativa in navigating its way in the sector and advise on investments ahead of anticipated regulatory change in Europe, including the UK.

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “Since Sativa’s listing, the market has had a governmental and societal sea change of attitudes to medicinal cannabis. In the past two weeks, the UK has seen the two high profile cases of Alfie Dingley and Billy Caldwell, two young boys who suffer from rare forms of epilepsy and need medicinal cannabis for their treatment, which was initially rejected to them by the UK authorities, generating widespread consternation and condemnation. In both cases, the Home Secretary then intervened and issued a licence from the Home Office.

“It is hard to see how the UK’s stance and that of a few other leading EU countries, which are also resisting medicinal advanced therapy, can continue without accepting that the controlled use of medicinal cannabis has an important part to play in healthcare.”

The Directors of the Company accept responsibility for the contents of this announcement.

 

– Ends  –

 

For further information please contact:

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/